{"product_id":"abt-business-model-canvas","title":"Abbott Laboratories (ABT): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas gives you a clear, research-based view of how Abbott Laboratories creates and grows value through healthcare providers, diagnostic labs, suppliers, regulators, and global distribution partners. You'll see how a \u003cstrong\u003e115,000\u003c\/strong\u003e-employee base, \u003cstrong\u003e90+\u003c\/strong\u003e manufacturing facilities, FDA and CE-approved technologies, and Exact Sciences integration support medical device R\u0026amp;D, diagnostics, AI-enabled lab analytics, and supply across \u003cstrong\u003e160+\u003c\/strong\u003e countries. It breaks down the main customer groups, from hospitals and clinics to diabetes and cancer screening patients, while showing how revenue comes from medical devices, diagnostics, nutrition, established pharmaceuticals, and cancer diagnostics. It also highlights the biggest cost drivers, including R\u0026amp;D, manufacturing, CAPEX, integration, compliance, and logistics.\u003c\/p\u003e\u003ch2\u003eAbbott Laboratories - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\u003cp\u003eAbbott Laboratories depends on a partnership network that spans \u003cstrong\u003e4\u003c\/strong\u003e business segments, operations in \u003cstrong\u003emore than 160\u003c\/strong\u003e countries, and about \u003cstrong\u003e114,000\u003c\/strong\u003e employees. Hospitals, laboratories, suppliers, regulators, and logistics providers determine whether Abbott's products are approved, ordered, reimbursed, stocked, and used.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership area\u003c\/th\u003e\n\u003cth\u003eReal-life Abbott scale\u003c\/th\u003e\n\u003cth\u003eBusiness model role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare providers and hospitals\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e business segments; presence in \u003cstrong\u003emore than 160\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eClinical adoption, prescribing, implantation, reimbursement, patient follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostic laboratories and screening networks\u003c\/td\u003e\n\u003ctd\u003eGlobal reach in \u003cstrong\u003emore than 160\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eHigh-volume testing, sample processing, screening access, turnaround-time performance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers and manufacturing partners\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e114,000\u003c\/strong\u003e employees\u003c\/td\u003e\n\u003ctd\u003eRaw materials, electronics, reagents, packaging, quality control, production continuity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory bodies and approvals\u003c\/td\u003e\n\u003ctd\u003eFDA, EMA, PMDA, MHRA, Health Canada, TGA, ANVISA, NMPA\u003c\/td\u003e\n\u003ctd\u003eMarket entry, labeling, safety oversight, launch timing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution and logistics networks\u003c\/td\u003e\n\u003ctd\u003eSales and distribution in \u003cstrong\u003emore than 160\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eWarehousing, customs, cold chain, last-mile delivery, local service\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHealthcare providers and hospitals\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHospitals, cath labs, electrophysiology labs, diabetes clinics, and primary care groups are the most important clinical partners for Abbott Laboratories. These partners decide whether devices are adopted, whether tests are ordered, and whether patients stay on therapy. In Medical Devices, the relationship is built around procedure performance, training, and follow-up support. In Diagnostics, the relationship is built around test placement, turnaround time, and workflow. In Nutrition, the relationship is built around pediatric, adult, and clinical nutrition use in hospital and outpatient settings. In Established Pharmaceuticals, physicians and hospital formularies shape access and repeat use. Group purchasing organizations, or GPOs, and integrated delivery networks, or IDNs, matter because they can contract for many facilities at once.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e segments mean Abbott must manage different provider relationships by product line.\u003c\/li\u003e\n\u003cli\u003eHospital systems can standardize products across multiple sites, so one contract can matter more than one purchase order.\u003c\/li\u003e\n\u003cli\u003eClinical training is part of the partnership because many Abbott products depend on correct use and follow-up.\u003c\/li\u003e\n\u003cli\u003eReimbursement access is critical because hospitals and clinics often need payment approval before wide adoption.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDiagnostic laboratories and screening networks\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLaboratories and screening networks are central partners for Abbott Laboratories' Diagnostics business. Core labs, public health labs, blood screening centers, and point-of-care sites use Abbott systems to process large sample volumes and deliver fast results. Abbott's diagnostic platforms sit inside routine clinical workflows, so the partnership is not just about selling a test kit. It is about instrument placement, reagent supply, service uptime, and data workflow. That matters because a lab that trusts uptime and turnaround time is more likely to reorder, expand menu breadth, and standardize on one platform across multiple sites.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eLab partnerships reduce the gap between sample collection and treatment decisions.\u003c\/li\u003e\n\u003cli\u003eScreening networks increase the number of patients reached without adding hospital visits.\u003c\/li\u003e\n\u003cli\u003ePoint-of-care settings support faster decisions in urgent care, emergency, and outpatient environments.\u003c\/li\u003e\n\u003cli\u003eOngoing reagent supply and service contracts matter because lab systems need predictable operating continuity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSuppliers and manufacturing partners\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbbott Laboratories depends on suppliers of raw materials, electronics, reagents, plastics, packaging, sterile components, and specialized services. Manufacturing partners matter because regulated healthcare products cannot be treated like standard consumer goods. Quality control, traceability, and consistency are part of the product itself. Abbott's scale, with about \u003cstrong\u003e114,000\u003c\/strong\u003e employees and operations in \u003cstrong\u003emore than 160\u003c\/strong\u003e countries, means the supply chain has to support multiple product types and regional rules at the same time. That makes dual sourcing, regional manufacturing, and supplier qualification strategically important.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eElectronics suppliers matter for monitoring and connected devices.\u003c\/li\u003e\n\u003cli\u003eReagent and consumable suppliers matter for diagnostics volume and consistency.\u003c\/li\u003e\n\u003cli\u003ePackaging and sterile-component suppliers matter because product integrity affects safety and shelf life.\u003c\/li\u003e\n\u003cli\u003eManufacturing partners must meet quality and validation requirements before products can move at scale.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory bodies and approvals\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRegulatory agencies are a core partnership layer because Abbott cannot sell many products without approvals or clearances. The main bodies include the FDA in the U.S., the EMA in Europe for medicines, PMDA in Japan, MHRA in the U.K., Health Canada, TGA in Australia, ANVISA in Brazil, and NMPA in China. These relationships shape launch timing, labeling, post-market monitoring, and product changes. For a company that sells across \u003cstrong\u003emore than 160\u003c\/strong\u003e countries, regulatory work is not a back-office task. It is part of revenue access.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eFDA decisions affect U.S. access for devices, diagnostics, and some tests.\u003c\/li\u003e\n\u003cli\u003eCE marking and European regulatory pathways affect access across European markets.\u003c\/li\u003e\n\u003cli\u003eCountry-specific approvals change launch timing and can delay or expand product rollout.\u003c\/li\u003e\n\u003cli\u003ePost-market surveillance is important because regulators can require follow-up data after launch.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDistribution and logistics networks\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbbott Laboratories needs wholesalers, distributors, hospital supply systems, pharmacies, freight carriers, and cold-chain logistics providers to move products across its global network. This matters because the company sells in \u003cstrong\u003emore than 160\u003c\/strong\u003e countries, and each market has different import rules, customs procedures, storage requirements, and service expectations. Distribution partnerships are especially important for diagnostics, nutrition, and products that need controlled storage or rapid replenishment. Last-mile delivery determines whether products reach hospitals, labs, and pharmacies on time.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eWholesalers and distributors help Abbott reach smaller hospitals, clinics, and pharmacies.\u003c\/li\u003e\n\u003cli\u003eHospital supply chains are critical for routine stock availability and emergency demand.\u003c\/li\u003e\n\u003cli\u003eCold-chain partners matter for temperature-sensitive products.\u003c\/li\u003e\n\u003cli\u003eCustoms brokers and freight providers reduce delays in cross-border movement.\u003c\/li\u003e\n\u003cli\u003eE-commerce and retail pharmacy channels matter for selected consumer and home-use products.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAbbott Laboratories - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\u003cp\u003eAbbott Laboratories runs \u003cstrong\u003e4\u003c\/strong\u003e reportable businesses, operates in more than \u003cstrong\u003e160\u003c\/strong\u003e countries, and had about \u003cstrong\u003e113,000\u003c\/strong\u003e employees. Its key activities are regulated R\u0026amp;D, clinical testing, manufacturing, quality control, and connected diagnostics.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey activity\u003c\/th\u003e\n\u003cth\u003eReal-life numeric anchors\u003c\/th\u003e\n\u003cth\u003eBusiness model role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical device R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e14\u003c\/strong\u003e-day sensor wear; \u003cstrong\u003e1\u003c\/strong\u003e-minute glucose readings; \u003cstrong\u003e4\u003c\/strong\u003e reportable businesses\u003c\/td\u003e\n\u003ctd\u003eBuilds device features, sensor performance, and product pipelines for diabetes and cardiovascular care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics development and testing\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e diagnostics categories: core laboratory, molecular diagnostics, rapid diagnostics, and point-of-care\u003c\/td\u003e\n\u003ctd\u003eCreates, validates, and refreshes assays, instruments, and test menus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal manufacturing and supply chain\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e160\u003c\/strong\u003e countries; about \u003cstrong\u003e113,000\u003c\/strong\u003e employees; \u003cstrong\u003e$40.1\u003c\/strong\u003e billion net sales in 2023\u003c\/td\u003e\n\u003ctd\u003eSupports scale, continuity, quality, and on-time delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExact Sciences integration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e separate Exact Sciences operating segment disclosed; activity sits inside the \u003cstrong\u003e4\u003c\/strong\u003e reportable businesses\u003c\/td\u003e\n\u003ctd\u003eMoves diagnostics work from development into routine clinical use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI-enabled lab analytics\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e standalone AI revenue line disclosed; analytics is embedded in diagnostics software and instrument automation\u003c\/td\u003e\n\u003ctd\u003eImproves flagging, quality control, uptime, and workflow speed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eMedical device R\u0026amp;D is centered on glucose sensing, cardiovascular devices, and miniaturized electronics. The clearest product-level numbers are \u003cstrong\u003e14\u003c\/strong\u003e-day wear and \u003cstrong\u003e1\u003c\/strong\u003e-minute readings, which means Abbott Laboratories has to keep sensor chemistry, firmware, and data transmission stable over long wear cycles.\u003c\/p\u003e\n\n\u003cp\u003eDiagnostics development and testing sits across \u003cstrong\u003e4\u003c\/strong\u003e major lanes: core laboratory, molecular diagnostics, rapid diagnostics, and point-of-care. This matters because each lane has different sample types, turnaround times, and quality-control rules, so one test platform cannot be treated like another.\u003c\/p\u003e\n\n\u003cp\u003eGlobal manufacturing and supply chain work is large enough to affect the whole model. Abbott Laboratories reported \u003cstrong\u003e$40.1\u003c\/strong\u003e billion in net sales in 2023, operated in more than \u003cstrong\u003e160\u003c\/strong\u003e countries, and had about \u003cstrong\u003e113,000\u003c\/strong\u003e employees. That scale makes procurement, plant scheduling, inventory, and distribution core activities rather than support tasks.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSupplier qualification for regulated components\u003c\/li\u003e\n\u003cli\u003eLot release and quality testing\u003c\/li\u003e\n\u003cli\u003eInventory positioning across regions\u003c\/li\u003e\n\u003cli\u003eDistribution planning for devices and diagnostics kits\u003c\/li\u003e\n\u003cli\u003eTraceability for recalls and field actions\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eExact Sciences integration is not disclosed as a separate Abbott Laboratories segment, so it belongs inside diagnostics development. The practical work is integration of test design, validation, workflow fit, and compliance across the \u003cstrong\u003e4\u003c\/strong\u003e diagnostics categories.\u003c\/p\u003e\n\n\u003cp\u003eAI-enabled lab analytics is also embedded rather than reported separately. Abbott Laboratories does not present a standalone AI revenue line, so the activity shows up through diagnostics software, automation, and connected instrument data rather than through a separate business unit.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eFaster flagging of out-of-range results\u003c\/li\u003e\n\u003cli\u003eQuality-control checks\u003c\/li\u003e\n\u003cli\u003eInstrument uptime monitoring\u003c\/li\u003e\n\u003cli\u003eRemote service and calibration support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eAbbott Laboratories - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e114,000\u003c\/strong\u003e employees, \u003cstrong\u003e90+\u003c\/strong\u003e manufacturing facilities, \u003cstrong\u003e160+\u003c\/strong\u003e countries, and \u003cstrong\u003e4\u003c\/strong\u003e business segments are the core resources behind Abbott Laboratories.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eLatest real-life figure\u003c\/th\u003e\n\u003cth\u003eBusiness model role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e114,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D, manufacturing, regulatory, and commercial execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing network\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e90+\u003c\/strong\u003e facilities\u003c\/td\u003e\n\u003ctd\u003eProduction scale, quality control, and supply continuity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic reach\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e160+\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eDistribution and market access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating structure\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e segments\u003c\/td\u003e\n\u003ctd\u003eMedical Devices, Diagnostics, Nutrition, Established Pharmaceuticals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory access\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e major systems: FDA and CE\u003c\/td\u003e\n\u003ctd\u003eU.S. and European market entry for regulated products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial scale\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$42.0 billion\u003c\/strong\u003e net sales in 2024\u003c\/td\u003e\n\u003ctd\u003eFunding for capital spending, product development, and operations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003e4\u003c\/strong\u003e business segments define the portfolio base: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e114,000\u003c\/strong\u003e employees\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e90+\u003c\/strong\u003e manufacturing facilities\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e160+\u003c\/strong\u003e countries\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e business segments\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e major regulatory systems: FDA and CE\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$42.0 billion\u003c\/strong\u003e in 2024 net sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFDA-approved and CE-marked technologies sit inside Abbott Laboratories' regulated resource base and support market access across \u003cstrong\u003e2\u003c\/strong\u003e major approval systems.\u003c\/p\u003e\u003ch2\u003eAbbott Laboratories - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$40.1B\u003c\/strong\u003e in 2023 net sales, \u003cstrong\u003e4\u003c\/strong\u003e major businesses, \u003cstrong\u003e160+\u003c\/strong\u003e countries, \u003cstrong\u003e14\u003c\/strong\u003e-day CGM wear, \u003cstrong\u003e1\u003c\/strong\u003e-minute glucose updates, and rapid test results in \u003cstrong\u003e6\u003c\/strong\u003e to \u003cstrong\u003e13\u003c\/strong\u003e minutes define Abbott Laboratories' value proposition.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue proposition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life number(s)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAbbott Laboratories example\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContinuous glucose monitoring and biowearables\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e14\u003c\/strong\u003e days; \u003cstrong\u003e1\u003c\/strong\u003e minute; \u003cstrong\u003e1,440\u003c\/strong\u003e readings per day\u003c\/td\u003e\n\u003ctd\u003eFreeStyle Libre 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBroad healthcare portfolio\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e businesses; \u003cstrong\u003e$40.1B\u003c\/strong\u003e 2023 net sales\u003c\/td\u003e\n\u003ctd\u003eMedical Devices, Diagnostics, Nutrition, Established Pharmaceuticals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer screening and diagnostics\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e minutes; \u003cstrong\u003e13\u003c\/strong\u003e minutes\u003c\/td\u003e\n\u003ctd\u003eID NOW\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaster lab turnaround with AI\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e minutes; \u003cstrong\u003e13\u003c\/strong\u003e minutes\u003c\/td\u003e\n\u003ctd\u003eID NOW and diagnostics automation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocalized supply in 160+ countries\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e160+\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eAbbott Laboratories global footprint\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eContinuous glucose monitoring and biowearables\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFreeStyle Libre 3 provides glucose readings every \u003cstrong\u003e1\u003c\/strong\u003e minute for up to \u003cstrong\u003e14\u003c\/strong\u003e days, equal to as many as \u003cstrong\u003e1,440\u003c\/strong\u003e readings per day. The sensor replaces episodic fingerstick testing with a continuous data stream.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e14\u003c\/strong\u003e-day sensor wear\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e-minute updates\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,440\u003c\/strong\u003e readings per day\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe recurring replacement cycle supports repeat use and creates a product model built around regular sensor replenishment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBroad healthcare portfolio\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbbott Laboratories operates \u003cstrong\u003e4\u003c\/strong\u003e major businesses: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. 2023 net sales were \u003cstrong\u003e$40.1B\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e major businesses\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$40.1B\u003c\/strong\u003e 2023 net sales\u003c\/li\u003e\n\u003cli\u003eMedical Devices\u003c\/li\u003e\n\u003cli\u003eDiagnostics\u003c\/li\u003e\n\u003cli\u003eNutrition\u003c\/li\u003e\n\u003cli\u003eEstablished Pharmaceuticals\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCancer screening and diagnostics\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbbott Laboratories' diagnostics business supports screening and testing across lab and point-of-care settings. ID NOW delivers results in as little as \u003cstrong\u003e6\u003c\/strong\u003e minutes for positive samples and \u003cstrong\u003e13\u003c\/strong\u003e minutes for negative samples.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e-minute positive result time\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e13\u003c\/strong\u003e-minute negative result time\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFaster lab turnaround with AI\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbbott Laboratories shortens turnaround through diagnostics automation and rapid molecular testing. The measurable result is the same ID NOW timing: \u003cstrong\u003e6\u003c\/strong\u003e minutes and \u003cstrong\u003e13\u003c\/strong\u003e minutes.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMetric\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFigure\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePlatform\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePositive result time\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e minutes\u003c\/td\u003e\n\u003ctd\u003eID NOW\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNegative result time\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13\u003c\/strong\u003e minutes\u003c\/td\u003e\n\u003ctd\u003eID NOW\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlucose update frequency\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e minute\u003c\/td\u003e\n\u003ctd\u003eFreeStyle Libre 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor wear\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e14\u003c\/strong\u003e days\u003c\/td\u003e\n\u003ctd\u003eFreeStyle Libre 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eLocalized supply in 160+ countries\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbbott Laboratories sells products in \u003cstrong\u003e160+\u003c\/strong\u003e countries. That footprint supports local availability of devices, diagnostics, and nutrition products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e160+\u003c\/strong\u003e countries served\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$40.1B\u003c\/strong\u003e 2023 net sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e business segments\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAbbott Laboratories - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$42.0 billion\u003c\/strong\u003e in 2024 net sales, \u003cstrong\u003e$40.1 billion\u003c\/strong\u003e in 2023 net sales, operations in \u003cstrong\u003e160+\u003c\/strong\u003e countries, and a workforce of \u003cstrong\u003e114,000\u003c\/strong\u003e show a relationship model built on repeat use, training, and account coverage.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical support and training\u003c\/strong\u003e is a recurring relationship because device onboarding, use, and follow-up happen after the sale. A digital diabetes user base of \u003cstrong\u003e5 million+\u003c\/strong\u003e people across \u003cstrong\u003e60+\u003c\/strong\u003e countries means the relationship extends beyond distribution into education, setup, and data review.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e5 million+\u003c\/strong\u003e users\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e60+\u003c\/strong\u003e countries\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e114,000\u003c\/strong\u003e employees\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eConsumer app-based engagement\u003c\/strong\u003e turns monitoring into repeated daily contact. In chronic care, that means the customer is not just a buyer but an ongoing user, which raises retention value when the same person returns for readings, alerts, and data sharing across \u003cstrong\u003e60+\u003c\/strong\u003e countries.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLong-term provider relationships\u003c\/strong\u003e are visible in Abbott Laboratories' sales base: \u003cstrong\u003e$40.1 billion\u003c\/strong\u003e in 2023 and \u003cstrong\u003e$42.0 billion\u003c\/strong\u003e in 2024, a difference of \u003cstrong\u003e$1.9 billion\u003c\/strong\u003e or \u003cstrong\u003e4.7%\u003c\/strong\u003e. That scale points to recurring orders from hospitals, clinics, labs, and payers.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical support and training\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5 million+\u003c\/strong\u003e; \u003cstrong\u003e60+\u003c\/strong\u003e; \u003cstrong\u003e114,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer app-based engagement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5 million+\u003c\/strong\u003e; \u003cstrong\u003e60+\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term provider relationships\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$40.1 billion\u003c\/strong\u003e; \u003cstrong\u003e$42.0 billion\u003c\/strong\u003e; \u003cstrong\u003e4.7%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOngoing screening follow-up\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e38.4 million\u003c\/strong\u003e; \u003cstrong\u003e97.6 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnterprise account management\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e; \u003cstrong\u003e160+\u003c\/strong\u003e; \u003cstrong\u003e114,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOngoing screening follow-up\u003c\/strong\u003e is anchored in disease burden. In the U.S., \u003cstrong\u003e38.4 million\u003c\/strong\u003e people live with diabetes and \u003cstrong\u003e97.6 million\u003c\/strong\u003e adults have prediabetes, so screening and retesting can repeat for years. That keeps the customer relationship active after the first test or first device purchase.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e38.4 million\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e97.6 million\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eEnterprise account management\u003c\/strong\u003e fits a company with \u003cstrong\u003e4\u003c\/strong\u003e operating segments, \u003cstrong\u003e160+\u003c\/strong\u003e countries, and \u003cstrong\u003e114,000\u003c\/strong\u003e employees. Those numbers support multi-site contracts, field support, and local service across large health systems and distribution networks.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e operating segments\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e160+\u003c\/strong\u003e countries\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e114,000\u003c\/strong\u003e employees\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$42.0 billion\u003c\/strong\u003e 2024 net sales\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAbbott Laboratories - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003eAbbott Laboratories' channel system sits on \u003cstrong\u003e$42.0 billion\u003c\/strong\u003e in 2024 net sales, \u003cstrong\u003e4\u003c\/strong\u003e reporting segments, and commercial reach in more than \u003cstrong\u003e160\u003c\/strong\u003e countries. The mix combines direct hospital selling, diagnostic field sales, retail and distributor access, and digital platforms tied to connected devices.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eChannel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMain buyers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCommercial role\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life anchor\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect hospital sales\u003c\/td\u003e\n\u003ctd\u003eHospitals, cath labs, operating rooms, heart centers\u003c\/td\u003e\n\u003ctd\u003eProcedure-based device selling with clinical support\u003c\/td\u003e\n\u003ctd\u003ePart of 2024 net sales of \u003cstrong\u003e$42.0 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostic lab sales force\u003c\/td\u003e\n\u003ctd\u003eClinical laboratories, reference labs, blood banks\u003c\/td\u003e\n\u003ctd\u003eAnalyzer placement plus recurring reagent pull-through\u003c\/td\u003e\n\u003ctd\u003eOne of \u003cstrong\u003e4\u003c\/strong\u003e reporting segments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer wearable distribution\u003c\/td\u003e\n\u003ctd\u003ePatients, pharmacies, durable medical equipment suppliers\u003c\/td\u003e\n\u003ctd\u003eRecurring sensor replacement sales\u003c\/td\u003e\n\u003ctd\u003eMedical Devices revenue base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal distributor networks\u003c\/td\u003e\n\u003ctd\u003eLocal distributors, wholesalers, importers\u003c\/td\u003e\n\u003ctd\u003eMarket access across more than \u003cstrong\u003e160\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eKey route for established pharmaceuticals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital health platforms\u003c\/td\u003e\n\u003ctd\u003ePatients and clinicians\u003c\/td\u003e\n\u003ctd\u003eData sharing, follow-up, retention\u003c\/td\u003e\n\u003ctd\u003eSupports connected devices and repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect hospital sales.\u003c\/strong\u003e Abbott Laboratories sells procedure-based medical devices directly to hospitals, cath labs, operating rooms, and heart centers. This channel supports the Medical Devices business and usually includes clinical training, placement support, and post-sale service. It matters because direct selling gives Abbott Laboratories tighter control over adoption, pricing, and product use in high-acuity care settings.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospitals\u003c\/li\u003e\n\u003cli\u003eCath labs\u003c\/li\u003e\n\u003cli\u003eOperating rooms\u003c\/li\u003e\n\u003cli\u003eHeart centers\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDiagnostic lab sales force.\u003c\/strong\u003e Abbott Laboratories uses a specialized sales force for clinical laboratories, reference labs, hospitals, and blood banks. The channel is built around analyzer placements and recurring reagent and consumable demand, so the revenue profile is less one-off than capital equipment sales. It is one of the main routes behind the Diagnostics segment inside the \u003cstrong\u003e$42.0 billion\u003c\/strong\u003e company base.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eDiagnostic channel element\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBuyer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstrument placement\u003c\/td\u003e\n\u003ctd\u003eClinical labs\u003c\/td\u003e\n\u003ctd\u003eInstalled base\u003c\/td\u003e\n\u003ctd\u003eLocks in future consumable use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent supply\u003c\/td\u003e\n\u003ctd\u003eHospitals and labs\u003c\/td\u003e\n\u003ctd\u003eRecurring\u003c\/td\u003e\n\u003ctd\u003eSupports repeat orders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService and maintenance\u003c\/td\u003e\n\u003ctd\u003eTesting sites\u003c\/td\u003e\n\u003ctd\u003eContract-based\u003c\/td\u003e\n\u003ctd\u003eKeeps systems running\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePoint-of-care systems\u003c\/td\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eConsumable-driven\u003c\/td\u003e\n\u003ctd\u003eLinks tests to daily workflows\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eConsumer wearable distribution.\u003c\/strong\u003e Abbott Laboratories sells continuous glucose monitoring systems through pharmacies, durable medical equipment suppliers, and digital ordering routes. That channel broadens access beyond hospitals and makes replacement sensors a recurring purchase. For Abbott Laboratories, the channel turns a medical device into a repeat-use product with patient and clinician data flowing through the same system.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRetail pharmacies\u003c\/li\u003e\n\u003cli\u003eDurable medical equipment suppliers\u003c\/li\u003e\n\u003cli\u003eDigital ordering\u003c\/li\u003e\n\u003cli\u003eClinician-guided follow-up\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal distributor networks.\u003c\/strong\u003e Abbott Laboratories uses distributors, wholesalers, and local commercial partners across more than \u003cstrong\u003e160\u003c\/strong\u003e countries. This channel is important where local registration, import handling, reimbursement, and fragmented retail structures make direct selling expensive. It is especially relevant for established pharmaceuticals and parts of nutrition and diagnostics outside the largest developed markets.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDigital health platforms.\u003c\/strong\u003e Abbott Laboratories connects devices to mobile and cloud platforms so patients and clinicians can view data, track trends, and support continued use. In channel terms, digital platforms do not replace physical distribution; they increase retention, simplify follow-up, and keep the product linked to the patient after the first sale.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMobile apps\u003c\/li\u003e\n\u003cli\u003eCloud dashboards\u003c\/li\u003e\n\u003cli\u003ePatient data sharing\u003c\/li\u003e\n\u003cli\u003eClinician follow-up\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eNumeric channel anchor\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eChannel meaning\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$42.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eScale behind the full channel mix\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 sales growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShows channel expansion versus the prior year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReporting segments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMedical Devices, Diagnostics, Nutrition, Established Pharmaceuticals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic reach\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e160+\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eRequires both direct and indirect routes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAbbott Laboratories - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\u003cp\u003eAbbott Laboratories serves \u003cstrong\u003e5\u003c\/strong\u003e customer segments here, and its commercial footprint spans more than \u003cstrong\u003e160\u003c\/strong\u003e countries. The largest recurring-use base is diabetes care, where the U.S. has \u003cstrong\u003e38.4\u003c\/strong\u003e million people with diabetes, including \u003cstrong\u003e29.7\u003c\/strong\u003e million diagnosed and \u003cstrong\u003e8.7\u003c\/strong\u003e million undiagnosed.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer segment\u003c\/td\u003e\n\u003ctd\u003ePrimary buyers or users\u003c\/td\u003e\n\u003ctd\u003eMain demand driver\u003c\/td\u003e\n\u003ctd\u003eQuantitative context\u003c\/td\u003e\n\u003ctd\u003eBusiness model effect\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals and clinics\u003c\/td\u003e\n\u003ctd\u003eProcurement teams, physicians, nurses, cath labs\u003c\/td\u003e\n\u003ctd\u003eDiagnostics, cardiovascular devices, inpatient nutrition\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e160\u003c\/strong\u003e countries; \u003cstrong\u003e4\u003c\/strong\u003e care settings: emergency, intensive care, operating room, cath lab\u003c\/td\u003e\n\u003ctd\u003eInstitutional contracts and recurring consumables\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostic laboratories\u003c\/td\u003e\n\u003ctd\u003eLab directors, pathologists, lab managers\u003c\/td\u003e\n\u003ctd\u003eChemistry, immunoassay, molecular, point-of-care testing\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e workflows\u003c\/td\u003e\n\u003ctd\u003eHigh test volume and repeat reagent sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumers and wellness users\u003c\/td\u003e\n\u003ctd\u003eParents, adults, older adults\u003c\/td\u003e\n\u003ctd\u003eNutrition products and self-care items\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e life stages: infants, children, adults, older adults\u003c\/td\u003e\n\u003ctd\u003eRetail, pharmacy, club, and online repeat purchases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes patients\u003c\/td\u003e\n\u003ctd\u003ePatients, caregivers, endocrinology clinics\u003c\/td\u003e\n\u003ctd\u003eContinuous glucose monitoring and digital tools\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e38.4\u003c\/strong\u003e million U.S. people with diabetes; \u003cstrong\u003e11.6%\u003c\/strong\u003e of the U.S. population; \u003cstrong\u003e29.7\u003c\/strong\u003e million diagnosed; \u003cstrong\u003e8.7\u003c\/strong\u003e million undiagnosed; more than \u003cstrong\u003e60\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eDaily use and long-term monitoring demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer screening patients\u003c\/td\u003e\n\u003ctd\u003ePhysicians, labs, screening patients\u003c\/td\u003e\n\u003ctd\u003eLaboratory screening and follow-up testing\u003c\/td\u003e\n\u003ctd\u003eAge \u003cstrong\u003e45\u003c\/strong\u003e; \u003cstrong\u003e152,810\u003c\/strong\u003e new U.S. colorectal cancer cases in \u003cstrong\u003e2024\u003c\/strong\u003e; \u003cstrong\u003e53,010\u003c\/strong\u003e deaths in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePrevention-led demand and follow-up testing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospitals and clinics\u003c\/strong\u003e buy through institutional procurement, so one sale can cover multiple departments at once. Abbott Laboratories serves this segment across \u003cstrong\u003e4\u003c\/strong\u003e main care settings: emergency, intensive care, operating room, and cath lab, which makes clinical uptime and repeat ordering more important than a one-time sale.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e160+\u003c\/strong\u003e country reach supports global hospital purchasing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e care settings create broad clinical use.\u003c\/li\u003e\n\u003cli\u003eRecurring consumables matter because installed systems usually generate repeat sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDiagnostic laboratories\u003c\/strong\u003e buy analyzers, assays, and reagents based on test volume and turnaround time. The segment centers on \u003cstrong\u003e4\u003c\/strong\u003e workflows: chemistry, immunoassay, molecular, and point-of-care testing, so Abbott Laboratories competes on accuracy, speed, and uptime.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e major workflows shape lab buying.\u003c\/li\u003e\n\u003cli\u003eHigh test volume raises the value of reagent contracts.\u003c\/li\u003e\n\u003cli\u003eFast turnaround matters because labs are paid to deliver results quickly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eConsumers and wellness users\u003c\/strong\u003e buy nutrition and self-care products through retail, pharmacy, club, and online channels. The relevant demand base spans \u003cstrong\u003e4\u003c\/strong\u003e life stages: infants, children, adults, and older adults, which means packaging, formulation, and price points need to vary by age group.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e life stages create different product needs.\u003c\/li\u003e\n\u003cli\u003eRepeat purchase frequency is higher than in one-time device sales.\u003c\/li\u003e\n\u003cli\u003eRetail shelf space and household trust matter more than hospital procurement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDiabetes patients\u003c\/strong\u003e are Abbott Laboratories's clearest recurring-use segment because glucose monitoring happens every day. In the U.S., \u003cstrong\u003e38.4\u003c\/strong\u003e million people have diabetes, equal to \u003cstrong\u003e11.6%\u003c\/strong\u003e of the population, with \u003cstrong\u003e29.7\u003c\/strong\u003e million diagnosed and \u003cstrong\u003e8.7\u003c\/strong\u003e million undiagnosed.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e38.4\u003c\/strong\u003e million U.S. patients define the addressable market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e29.7\u003c\/strong\u003e million diagnosed patients are the most direct buyers.\u003c\/li\u003e\n\u003cli\u003eMore than \u003cstrong\u003e60\u003c\/strong\u003e countries support global demand for continuous glucose monitoring.\u003c\/li\u003e\n\u003cli\u003eDaily monitoring makes this segment a strong source of repeat demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCancer screening patients\u003c\/strong\u003e are usually reached through physicians, laboratories, and follow-up care, not direct retail. In the U.S., colorectal cancer screening starts at age \u003cstrong\u003e45\u003c\/strong\u003e, and the American Cancer Society estimated \u003cstrong\u003e152,810\u003c\/strong\u003e new colorectal cancer cases and \u003cstrong\u003e53,010\u003c\/strong\u003e deaths in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eScreening begins at age \u003cstrong\u003e45\u003c\/strong\u003e, expanding the eligible population.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e152,810\u003c\/strong\u003e estimated new cases in \u003cstrong\u003e2024\u003c\/strong\u003e support ongoing screening demand.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e53,010\u003c\/strong\u003e estimated deaths in \u003cstrong\u003e2024\u003c\/strong\u003e show why early detection matters.\u003c\/li\u003e\n\u003cli\u003eThis segment often creates both one-time screening demand and repeat follow-up testing.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAbbott Laboratories - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\u003cp\u003eAbbott Laboratories' cost base is anchored by \u003cstrong\u003e$2.9B\u003c\/strong\u003e of R\u0026amp;D expense, about \u003cstrong\u003e$2.0B\u003c\/strong\u003e of capital expenditures, and a regulated footprint that reaches more than \u003cstrong\u003e160\u003c\/strong\u003e countries with about \u003cstrong\u003e114,000\u003c\/strong\u003e employees.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCost structure item\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eLatest disclosed figure\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCost meaning\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$42.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBase for absorbing fixed costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProduct development and pipeline funding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital expenditures\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePlants, equipment, and systems\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries served\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e160+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompliance and logistics burden\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e114,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePayroll and support cost base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition integration costs\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed\u003c\/td\u003e\n\u003ctd\u003eEmbedded in operating costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring and severance\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed\u003c\/td\u003e\n\u003ctd\u003eEmbedded in operating expenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eR\u0026amp;D spending\u003c\/strong\u003e was \u003cstrong\u003e$2.9B\u003c\/strong\u003e in 2024, or about \u003cstrong\u003e6.9%\u003c\/strong\u003e of \u003cstrong\u003e$42.0B\u003c\/strong\u003e in net sales. That level of spend shows that innovation is a recurring cost, not a one-time project, because Abbott has to keep funding product development across diagnostics, nutrition, medical devices, and pharmaceuticals.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.9B\u003c\/strong\u003e R\u0026amp;D expense\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e6.9%\u003c\/strong\u003e of \u003cstrong\u003e$42.0B\u003c\/strong\u003e sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$114,000\u003c\/strong\u003e employees supporting the development base\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and CAPEX\u003c\/strong\u003e sit next in the cost structure. Abbott reported \u003cstrong\u003e$2.0B\u003c\/strong\u003e of capital expenditures in 2024, equal to about \u003cstrong\u003e4.8%\u003c\/strong\u003e of \u003cstrong\u003e$42.0B\u003c\/strong\u003e in sales. In a business with regulated manufacturing, this spending supports plants, quality systems, automation, and capacity for global distribution.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.0B\u003c\/strong\u003e capital expenditures\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4.8%\u003c\/strong\u003e of \u003cstrong\u003e$42.0B\u003c\/strong\u003e sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e160+\u003c\/strong\u003e countries in the operating footprint\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcquisition integration costs\u003c\/strong\u003e are not shown as a single standalone total in the primary financial statements, so the hard numbers visible in the cost structure remain the recurring \u003cstrong\u003e$2.9B\u003c\/strong\u003e R\u0026amp;D spend and \u003cstrong\u003e$2.0B\u003c\/strong\u003e capex. The cost effect of acquisitions usually shows up through integration work, systems conversion, and acquired intangibles, but the latest public statement set does not give one consolidated number for that bucket.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRestructuring and severance\u003c\/strong\u003e also do not appear as a single standalone number in the primary statements. That means you should treat them as embedded operating costs rather than a separate canvas line item when you write about the model.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal compliance and logistics\u003c\/strong\u003e are structural costs in a business that operates in more than \u003cstrong\u003e160\u003c\/strong\u003e countries. The company also carries a workforce of about \u003cstrong\u003e114,000\u003c\/strong\u003e, which makes regulatory, quality, distribution, and payroll costs part of the normal cost base rather than one-off items.\u003c\/p\u003e\u003ch2\u003eAbbott Laboratories - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003eAbbott Laboratories reported \u003cstrong\u003e$42.0 billion\u003c\/strong\u003e in net sales in 2024 across \u003cstrong\u003e4\u003c\/strong\u003e reportable segments.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRevenue stream\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eShare of total net sales\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Devices\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutrition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstablished Pharmaceuticals\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer diagnostics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNo separate disclosure\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eIncluded in Diagnostics\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eMedical devices sales\u003c\/strong\u003e: \u003cstrong\u003e$20.2 billion\u003c\/strong\u003e in 2024. This was \u003cstrong\u003e48.1%\u003c\/strong\u003e of Abbott Laboratories' total net sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDiagnostics sales\u003c\/strong\u003e: \u003cstrong\u003e$9.7 billion\u003c\/strong\u003e in 2024. This was \u003cstrong\u003e23.1%\u003c\/strong\u003e of total net sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNutrition product sales\u003c\/strong\u003e: \u003cstrong\u003e$8.4 billion\u003c\/strong\u003e in 2024. This was \u003cstrong\u003e20.0%\u003c\/strong\u003e of total net sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEstablished pharmaceuticals sales\u003c\/strong\u003e: \u003cstrong\u003e$3.7 billion\u003c\/strong\u003e in 2024. This was \u003cstrong\u003e8.8%\u003c\/strong\u003e of total net sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCancer diagnostics sales\u003c\/strong\u003e: \u003cstrong\u003eNo separate disclosure\u003c\/strong\u003e; included in the \u003cstrong\u003e$9.7 billion\u003c\/strong\u003e Diagnostics segment.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$20.2 billion\u003c\/strong\u003e Medical Devices\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$9.7 billion\u003c\/strong\u003e Diagnostics\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$8.4 billion\u003c\/strong\u003e Nutrition\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$3.7 billion\u003c\/strong\u003e Established Pharmaceuticals\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNo separate disclosure\u003c\/strong\u003e Cancer diagnostics\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601581142165,"sku":"abt-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/abt-business-model-canvas.png?v=1740140837","url":"https:\/\/dcf-model.com\/products\/abt-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}